183 related articles for article (PubMed ID: 36472587)
21. miR-149 Suppresses Breast Cancer Metastasis by Blocking Paracrine Interactions with Macrophages.
Sánchez-González I; Bobien A; Molnar C; Schmid S; Strotbek M; Boerries M; Busch H; Olayioye MA
Cancer Res; 2020 Mar; 80(6):1330-1341. PubMed ID: 31911555
[TBL] [Abstract][Full Text] [Related]
22. Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes.
Xu B; Sun H; Song X; Liu Q; Jin W
Front Immunol; 2022; 13():923481. PubMed ID: 35844580
[TBL] [Abstract][Full Text] [Related]
23. OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression.
Zhang Y; Fan Y; Jing X; Zhao L; Liu T; Wang L; Zhang L; Gu S; Zhao X; Teng Y
Cancer Lett; 2021 Apr; 504():104-115. PubMed ID: 33587979
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
25. Targeting prooxidant MnSOD effect inhibits triple-negative breast cancer (TNBC) progression and M2 macrophage functions under the oncogenic stress.
Al Haq AT; Tseng HY; Chen LM; Wang CC; Hsu HL
Cell Death Dis; 2022 Jan; 13(1):49. PubMed ID: 35017469
[TBL] [Abstract][Full Text] [Related]
26. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
27. Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Wang Y; Zhang X; Xie X; Chen W; Li M; Diao D; Dang C
Cancer Biol Ther; 2020 Dec; 21(12):1179-1190. PubMed ID: 33218268
[TBL] [Abstract][Full Text] [Related]
28. Tribbles homolog 1 deficiency modulates function and polarization of murine bone marrow-derived macrophages.
Arndt L; Dokas J; Gericke M; Kutzner CE; Müller S; Jeromin F; Thiery J; Burkhardt R
J Biol Chem; 2018 Jul; 293(29):11527-11536. PubMed ID: 29899113
[TBL] [Abstract][Full Text] [Related]
29. Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway.
Uluer ET; Aydemir I; Inan S; Ozbilgin K; Vatansever HS
Acta Histochem; 2012 Nov; 114(7):641-6. PubMed ID: 22172707
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
[TBL] [Abstract][Full Text] [Related]
31. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
Kim S; Choi I; Han IH; Bae H
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555393
[TBL] [Abstract][Full Text] [Related]
33. TRIM21-mediated Sohlh2 ubiquitination suppresses M2 macrophage polarization and progression of triple-negative breast cancer.
Zhang R; Shen Y; Zhang Q; Feng X; Liu X; Huo X; Sun J; Hao J
Cell Death Dis; 2023 Dec; 14(12):850. PubMed ID: 38123542
[TBL] [Abstract][Full Text] [Related]
34. Macrophage Colony-stimulating Factor Mediates the Recruitment of Macrophages in Triple negative Breast Cancer.
Lu X; Yang R; Zhang L; Xi Y; Zhao J; Wang F; Zhang H; Li Z
Int J Biol Sci; 2019; 15(13):2859-2871. PubMed ID: 31853223
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
37. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways.
Zhou D; Huang C; Lin Z; Zhan S; Kong L; Fang C; Li J
Cell Signal; 2014 Feb; 26(2):192-7. PubMed ID: 24219909
[TBL] [Abstract][Full Text] [Related]
38. Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.
Chen M; Miao Y; Qian K; Zhou X; Guo L; Qiu Y; Wang R; Gan Y; Zhang X
Nano Lett; 2021 Jul; 21(14):6031-6041. PubMed ID: 34240603
[TBL] [Abstract][Full Text] [Related]
39. miR-200c/PAI-2 promotes the progression of triple negative breast cancer via M1/M2 polarization induction of macrophage.
Meng Z; Zhang R; Wang Y; Zhu G; Jin T; Li C; Zhang S
Int Immunopharmacol; 2020 Apr; 81():106028. PubMed ID: 31801690
[TBL] [Abstract][Full Text] [Related]
40. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
